Dr. Lal Path Labs · NSE: LALPATHLAB · BSE: 539524
Q4 FY21 results · Jan–Mar 2021
Dr. Lal Path Labs reported revenue from operations of ₹431.00 crore (up 42.9% from Q4 FY20) and net profit of ₹85.10 crore (up 161.0% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 431.00 | 301.70 | +42.9% | 452.40 | −4.7% |
| Other income | 13.50 | 12.00 | +12.5% | 13.50 | +0.0% |
| Total income | 444.50 | 313.70 | +41.7% | 465.90 | −4.6% |
| Profit before tax | 110.80 | 45.40 | +144.1% | 128.90 | −14.0% |
| Net profit for the period | 85.10 | 32.60 | +161.0% | 95.90 | −11.3% |
| Attributable to shareholders of the company | 83.40 | 32.50 | +156.6% | 94.50 | −11.7% |
| EPS, basic (₹) | 10.10 | 3.94 | +156.3% | 11.44 | −11.7% |
| Net margin (%) | 19.7 | 10.8 | 21.2 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 404.10 | 287.50 | +40.6% | 427.10 | −5.4% |
| Other income | 13.10 | 14.00 | −6.4% | 14.60 | −10.3% |
| Total income | 417.20 | 301.50 | +38.4% | 441.70 | −5.5% |
| Profit before tax | 104.70 | 47.60 | +120.0% | 124.10 | −15.6% |
| Net profit for the period | 78.70 | 35.30 | +122.9% | 92.70 | −15.1% |
| EPS, basic (₹) | 9.52 | 4.28 | +122.4% | 11.23 | −15.2% |
| Net margin (%) | 19.5 | 12.3 | 21.7 |
Consolidated
- Filed with BSE
- 21 May 2021, 18:09 IST
- Board meeting
- 21 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 21 May 2021, 18:09 IST
- Board meeting
- 21 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE